@prefix nkg: . @prefix nt: . @prefix orcid: . @prefix bl: . @prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "Similarly, De Cos Milas et al. [6] described their clinical experience with paliperidone in adolescents. They presented 3 males and 2 females, age between 15 and 17 years. Diagnoses were autism, borderline personality disorder, schizotypal personality disorder, personality disorder not otherwise specified, and schizophrenia. Prescribed dose was 3–9 mg/day, and actual mean time of treatment duration is 5.8 months. In 4 cases, paliperidone was initiated as a change from other antipsychotic. There were no adverse effects that required discontinuation and in all cases symptoms improved."; bl:has_population_context sub:context; bl:provided_by ; bl:publications ; bl:relation nkg:OffLabelIndication . sub:context a bl:Cohort; rdfs:label "Adolescents (15-17)" . a bl:Drug . } sub:provenance { sub:assertion prov:generatedAtTime "2021-08-24T16:13:47.586648"^^xsd:dateTime . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "GqT07hBN6al0Vf9zMLUZYNzBCP2WgoGtVEi1VIIjzx7DszQkCsPChUxAeFYXFkkJTi/Z/qgmVFi2SvV79CLKc13RJvQXvBfyFBBGGGCFmfnKTMBESghqW8/+WwQLkPz6tOUzfoJxKW5+LWXCcq5p2gN+XVWWYcOk9CFa/O50QMs="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-08-24T16:13:47.586648"^^xsd:dateTime; prov:wasAttributedTo orcid:0000-0002-7641-6446; nt:wasCreatedFromTemplate . }